Tscan Therapeutics is trading at $0.25, down 10.40%, with biotech-sector weakness a possible contributing factor; the available information does not establish a definitive cause.
- No company-specific announcement dated October 8 was identified; the latest press release listed by Tscan Therapeutics is dated September 2.
- The supplied sector update reports XBI down 2.04% during the session. Major-index declines were smaller, offering less direct context.